Promoter Fredun Medhora Converts ₹10 Cr Warrants to Boost Stake in Fredun Pharma

Fredun Pharmaceuticals is set to allot 1,06,668 equity shares to promoter Mr. Fredun Nariman Medhora. This follows his payment of the remaining ₹10.00 crore for converting warrants. The company's board approved the allotment on March 25, 2026.

The issuance adds ₹10.00 crore in capital and signals continued commitment from the promoter. The new shares will rank pari passu with existing shares.

Today's Decision: Board Approves Share Allotment

Fredun Pharmaceuticals' Board of Directors met on March 25, 2026, to approve allotting 1,06,668 equity shares to promoter Mr. Fredun Nariman Medhora. This action follows Mr. Medhora's payment of the balance due for warrants issued to him earlier.

The total amount paid for this conversion was ₹10,00,01,250 (approximately ₹10.00 crore). The shares were issued at ₹1,250 each, with a face value of ₹10.

These new shares carry the same rights as existing equity shares, ranking pari passu in all aspects. This conversion accounts for 1,06,668 of the 1,60,000 warrants originally allotted on December 29, 2025, leaving 53,332 warrants still outstanding.

Why This Matters

Converting warrants and allotting shares to a promoter signals strong confidence and commitment from the ownership group. This move also injects capital into the company, bolstering its financial standing.

For existing shareholders, this confirms the promoter's ongoing investment. It could also indicate future capital needs or strategic growth plans. The new shares rank pari passu, meaning existing shareholders' rights are not diluted.

Company Background and Past Funding

This warrant conversion is part of a broader preferential issue by Fredun Pharmaceuticals. On December 29, 2025, the company raised ₹97.49 crore by issuing equity shares and convertible warrants at ₹1,250 each. Promoters invested ₹25 crore in that round via warrants. Approval for these warrants was secured at an EGM on October 22, 2025.

Fredun Pharmaceuticals operates in the pharmaceutical sector, producing formulations, nutraceuticals, and exporting globally. Despite demonstrating long-term growth in sales and profits, the company has faced scrutiny. In June 2024, MarketsMOJO downgraded the stock to 'Sell' due to flat financial results and increased interest expenses.

Key Changes from This Allotment

• Promoter Stake Increase: Mr. Fredun Nariman Medhora's equity holding in Fredun Pharmaceuticals will increase upon this allotment.
• Capital Infusion: The company receives ₹10.00 crore in balance consideration for the converted warrants.
• Share Capital Growth: The total number of outstanding equity shares will increase by 1,06,668.
• Pari Passu Rights: The new shares carry identical rights to existing equity shares, ensuring no differential treatment.

Risks to Watch

Fredun Pharmaceuticals has a history of quality concerns, including medicines failing tests and warnings from bodies like the US FDA. Additionally, MarketsMOJO downgraded the stock to 'Sell' in June 2024, citing flat financials and rising interest costs. Investors should track the company's financial health and quality compliance.

Peer Comparison

Fredun Pharmaceuticals operates in the competitive Indian pharmaceutical landscape. Its peers include large-cap companies like Sun Pharmaceutical Industries, with a market cap of approximately ₹430,692 crore, and Torrent Pharmaceuticals, with a market cap of around ₹113,668 crore. These larger players often have diversified portfolios and broader global reach.

Key Metrics and Shareholding

• Promoter holding was approximately 43.1% as of December 2025.
• Mr. Fredun Nariman Medhora holds about 3.4% of the total promoter stake.
• TTM revenue stood at approximately $67.5 million, with TTM Net Profit around $3.75 million as of December 2025.

What to Track Next

• Outstanding Warrants: Monitor the conversion or expiry of the remaining 53,332 warrants.
• Promoter Shareholding: Track any further changes in the promoter group's stake post-allotment.
• Financial Performance: Keep an eye on quarterly results, particularly focusing on sales growth, profitability, and interest expenses, in light of past concerns.
• Regulatory Compliance: Observe any further developments or disclosures regarding drug quality and regulatory compliance.
• Company Expansion: Look for updates on the company's expansion plans funded by recent capital raises.